|  | Univariate analysis |  |  |  | Multivariate analysis |  |  | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Parameters | Number | HR | 95% C.I. | P value | Â | H.R. | 95% C.I. | P value | ||||
30-day survival (N = 751) |  |  |  |  |  |  |  |  | ||||
Sex | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 Male | 364 | 1.60 | 1.15–2.24 | 0.005 |  | 1.48 | 1.05–2.09 | 0.03 | ||||
 Female | 387 | 0.62 | 0.45–0.87 |  |  | 0.68 | 0.48–0.95 |  | ||||
Age | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ≤ 50 years | 471 | 0.51 | 0.37–0.70 | < 0.001 |  | 0.37 | 0.26–0.53 | < 0.001 | ||||
 > 50 years | 280 | 1.96 | 1.42–2.72 |  |  | 2.71 | 1.91–3.86 |  | ||||
Period of diagnosis | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 1991–1999 | 146 | 1.90 | 1.25–2.89 | 0.008 |  | 1.96 | 1.23–3.12 | 0.02 | ||||
 2000–2009 | 257 | 1.49 | 1.02–2.18 |  |  | 1.27 | 0.85–1.89 |  | ||||
 2010–2021 | 348 | 0.53 | 0.35–0.80 |  |  | 0.51 | 0.32–0.81 |  | ||||
Leucocyte count | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ≤ 10 × 109/L | 481 | 0.33 | 0.23–0.46 | < 0.001 |  | 0.32 | 0.23–0.45 | < 0.001 | ||||
 > 10 × 109/L | 253 | 3.09 | 2.20–4.32 |  |  | 3.14 | 2.23–4.43 |  | ||||
Induction regimens | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ATRA-based | 613 | 6.86 | 2.81–16.73 | < 0.001 |  | 6.14 | 2.44–15.43 | < 0.001 | ||||
 Oral-ATO-based | 138 | 0.15 | 0.06–0.36 |  |  | 0.16 | 0.07–0.41 |  | ||||
Overall survival (N = 751) |  |  |  |  |  |  |  |  | ||||
Sex | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 Male | 364 | 1.47 | 1.16–1.89 | 0.001 |  | 1.35 | 1.06–1.72 | 0.015 | ||||
 Female | 387 | 0.68 | 0.53–0.86 |  |  | 0.74 | 0.58–0.94 |  | ||||
Age | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ≤ 50 years | 471 | 0.49 | 0.39–0.62 | < 0.001 |  | 0.35 | 0.27–0.45 | < 0.001 | ||||
 > 50 years | 280 | 2.04 | 1.61–2.60 |  |  | 2.88 | 2.23–3.73 |  | ||||
Leucocyte count | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ≤ 10 × 109/L | 481 | 0.51 | 0.40–0.65 | < 0.001 |  | 0.51 | 0.39–0.65 | < 0.001 | ||||
 > 10 × 109/L | 253 | 1.98 | 1.55–2.52 |  |  | 1.98 | 1.54–2.54 |  | ||||
Sanz score | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 Low-risk | 142 | 0.66 | 0.47–0.91 | < 0.001 |  | 1.59 | 1.12–2.24 | 0.01 | ||||
 Intermediate-risk | 340 | 0.44 | 0.33–0.57 |  |  | 0.63 | 0.45–0.89 |  | ||||
 High-risk | 253 | 1.53 | 1.10–2.11 |  |  | 1.98 | 1.54–2.54 |  | ||||
Treatment regimens | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ATRA-based | 469 | 5.26 | 3.57–7.69 | < 0.001 |  | 5.56 | 3.84–8.33 | < 0.001 | ||||
 Oral-ATO-based | 282 | 0.19 | 0.13–0.28 |  |  | 0.18 | 0.12–0.26 |  | ||||
Post-30-day survival (N = 607) |  |  |  |  |  |  |  |  | ||||
Age | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ≤ 50 years | 402 | 0.45 | 0.31–0.64 | < 0.001 |  | 0.29 | 0.20–0.43 | < 0.001 | ||||
 > 50 years | 205 | 2.23 | 1.57–3.17 |  |  | 3.40 | 2.33–4.98 |  | ||||
Treatment regimens | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ATRA-based | 331 | 2.94 | 1.92–4.55 | < 0.001 |  | 3.03 | 1.82–5.26 | < 0.001 | ||||
 Oral-ATO-based | 276 | 0.34 | 0.22–0.52 |  |  | 0.33 | 0.19–0.55 |  | ||||
Relapse free survival (N = 607) |  |  |  |  |  |  |  |  | ||||
Period of diagnosis | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 1991–1999 | 107 | 4.38 | 2.34–8.16 | < 0.001 |  | 2.51 | 1.27–4.99 | < 0.001 | ||||
 2000–2009 | 203 | 4.52 | 2.58–7.90 |  |  | 3.40 | 1.90–6.09 |  | ||||
 2010–2021 | 297 | 0.23 | 0.12–0.43 |  |  | 0.40 | 0.25–0.73 |  | ||||
Treatment regimens | Â | Â | Â | Â | Â | Â | Â | Â | ||||
 ATRA-based | 331 | 3.45 | 2.13–5.56 | < 0.001 |  | 2.33 | 1.37–4.00 | 0.002 | ||||
 Oral-ATO-based | 276 | 0.29 | 0.18–0.47 |  |  | 0.43 | 0.25–0.73 |  |